口服避孕药开发商Afaxys获得800万美元融资，以推进使命并加速增长战略-动脉网

Afaxys Secures $8 Million to Advance Mission and Accelerate Growth Strategy

CISION 等信源发布 2025-08-04 20:30



可切换为仅中文







CHARLESTON, S.C.

查尔斯顿，南卡罗来纳州

，

Aug. 4, 2025

2025年8月4日

/PRNewswire/ -- Afaxys, Inc., a socially conscious healthcare company focused on serving the reproductive health needs of public health professionals and their patients, announces it has secured

/PRNewswire/ -- Afaxys, Inc.，一家专注于满足公共卫生专业人士及其患者生殖健康需求的社会责任型医疗保健公司，宣布已获得

$8 million

800万美元

in new funding from two large foundations to support its mission and propel its growth strategy. The capital includes a

来自两个大型基金会的新资金，以支持其使命并推动其增长战略。这笔资金包括

$3 million

300万美元

program-related investment (PRI) from the David and Lucile Packard Foundation and a

与项目相关的投资（PRI）来自大卫和露西尔·帕卡德基金会以及一个

$5 million

500万美元

grant from an anonymous foundation. This marks the third investment from the Packard Foundation since Afaxys was founded in 2008, underscoring the long-standing partnership and confidence in Afaxys' impact-driven model. 'Through our mission-based investments, Afaxys has grown into a durable and financially sustainable force in the market that will continue to actively ensure and continually expand reproductive health access for all patients, especially those served by public health providers,' said .

来自一家匿名基金会的资助。这是自Afaxys于2008年成立以来，帕卡德基金会的第三次投资，凸显了双方长期的合作伙伴关系以及对Afaxys以影响力为导向模式的信心。“通过我们的使命驱动型投资，Afaxys已成长为市场上一个持久且财务可持续的力量，将继续积极确保并不断扩大所有患者，特别是那些由公共卫生机构服务的患者的生殖健康获取渠道，”他表示。

Susan Phinney-Silver

苏珊·菲尼-西尔弗

, Mission Investing Director at the David and Lucile Packard Foundation

，大卫和露西尔·帕卡德基金会的任务投资总监

。

The new funding serves as a catalyst for growth as Afaxys continues its mission of providing millions of women in

新的资金作为增长的催化剂，Afaxys将继续其为数百万女性提供服务的使命

the United States

美国

access to affordable contraception. Afaxys is the only organization of its kind with an established, nationwide distribution infrastructure serving public health clinics. Afaxys plays a critical role in ensuring reliable supply chains for clinics that serve Medicaid and Title X patients. The funding will be used to complete the development of a novel contraceptive product, specifically designed to address the needs of marginalized communities and the more than 19 million women living in contraceptive deserts.

获得负担得起的避孕措施。Afaxys 是唯一一家拥有成熟全国分销基础设施的服务公共卫生诊所的组织。Afaxys 在确保为服务 Medicaid 和 Title X 患者的诊所提供可靠的供应链方面发挥着关键作用。这笔资金将用于完成一种新型避孕产品的开发，该产品专门设计用于满足边缘化社区和生活在避孕沙漠地区的超过 1900 万女性的需求。

'Access to quality reproductive healthcare has never been more critical. We are excited to partner with these esteemed foundations to further the Afaxys mission and ensure that access to reproductive healthcare is a right, not a privilege,' said .

“获得高质量的生殖健康护理从未如此重要。我们很高兴能与这些受人尊敬的基金会合作，进一步推动Afaxys的使命，确保获得生殖健康护理是一项权利，而不是特权，”该人士表示。

Ronda Dean

朗达·迪恩

, CEO of Afaxys, Inc

，Afaxys公司首席执行官

。

About Afaxys

关于Afaxys

Afaxys, a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients.

Afaxys是一家公共利益公司，与公共卫生和私营行业独特合作，确保医疗专业人员能够以稳定的价格可靠地获取他们为患者提供护理所需的产品和服务。

The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market.

Afaxys企业由三家全资子公司组成：Afaxys制药有限公司、Afaxys药物开发有限公司和Afaxys集团服务有限公司（AGS）。Afaxys制药向公共医疗市场提供广泛的品牌避孕药和仿制避孕药产品组合。

Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys' strategic goal of cost-conscious product commercialization. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization.

Afaxys药物开发提供药品的开发和监管服务，专注于快速且高效的上市准备，以推动Afaxys成本意识强的产品商业化的战略目标。AGS是一个战略采购业务，通过其集团采购组织，就广泛的产品和服务谈判获得优惠价格。

For more information, visit .

欲了解更多信息，请访问。

www.afaxys.com

。

Forward-Looking Statements

前瞻性声明

The statements in this press release that are not historical facts constitute 'forward-looking statements' as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements.

本新闻稿中的非历史事实的陈述构成了《联邦证券法》定义的“前瞻性陈述”。此类陈述受到风险和不确定性的约束，可能导致实际结果与这些前瞻性陈述所表达或暗示的未来结果存在重大差异。

Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made..

潜在风险和不确定性包括但不限于与无法实施战略举措相关的风险，以及对关键人员的依赖。前瞻性陈述仅在其作出之日有效。Afaxys, Inc. 不会更新前瞻性陈述以反映在作出前瞻性陈述后发生变化的事实假设、情况或事件。

Afaxys Media Contact

阿法克西斯媒体联系人

Green Room Communications

绿室通讯

gr_afaxys@grcomms.com

SOURCE Afaxys, Inc.

来源：Afaxys公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

是否刊登在PRNEWSWIRE.COM上？